The Resources Report: Natural Gas Stocks Ride Upcoming Wave of Oil Well Closures

Welcome to The Resources Report, with more coverage of emerging trends in the precious metals and energy investing space May 14, 2020   We are happy to provide our readership with a direct link to the Streetwise Reports. STREETWISE REPORTS FOR THURSDAY FOR MAY 14th  

The Resources Report: Brien Lundin: To Insure Yourself Against Financial Upheaval, Buy Gold & Silver Now

Welcome to The Resources Report, with more coverage of emerging trends in the precious metals and energy investing space May 12, 2020   We are happy to provide our readership with a direct link to the Streetwise Reports. STREETWISE REPORTS FOR TUESDAY MAY 12, 2020

The Resources Report: Mega Solar Project in Puerto Rico Moving Ahead

Welcome to The Resources Report, with more coverage of emerging trends in the precious metals and energy investing space April 30, 2020 We are happy to provide our readership with a direct link to the Streetwise Reports. STREETWISE REPORTS FOR THURSDAY, APRIL 30, 2020    

Investing in Life Sciences Under the Trump Presidency

Source: Kristin McFarland for The Life Sciences Report  (2/16/17) Stocks in all areas of life sciences including biotech to pharma have been on a roller coaster since Donald Trump won the election in November. Wealth advisor Kristin McFarland discusses the big picture for pharmaceutical investment under the new administration. As of February, a great deal of uncertainty still remains as firms—and the stock market—try to predict the Trump administration’s next moves. There is a lot on the table right now that could work for—or against—life sciences companies, specifically pharmaceuticals. What does the future hold for pharmaceuticals under President Trump? This is the billion dollar question that no one really knows the answer to. The president hasn’t announced anything yet but based on what we do know, changes could be good for the pharmaceutical industry, bad, or leave things mostly unchanged. Here’s a quick summary: – President Trump was not as outspoken about his plans to reduce prescription prices as Mrs. Clinton was but he has remarked that something needs to be done about the prices of medications – The president would like to see a streamlined FDA approval process and favors an overall reduction in regulations – Mr. Trump also ran on the desire to lower the tax rate, specifically on businesses – Mr. Trump has mentioned the possibility of allowing Americans to import lower cost drugs from outside the U.S. – President Trump’s recent travel ban could impact the ability and desire for scientists in the international community to come … Continue reading

19 Companies Selected for the 2017 Small-Cap Biotech Watchlist

Source: The Life Sciences Report  (1/3/17) Editors Note: Dudley Baker here with http://CommonStockWarrants.com Several of the companies mentioned below have stock warrants trading which are in our databases with complete details. If you like the company, you must love the stock warrants trading on those companies. ________________________________________________________________________________ Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January. The collection of small-cap biotechs on the 2017 Watchlist are developing therapies to address diverse indications including rare diseases, asthma, inflammatory bowel disease, spinal cord injury, hemophilia, and a number of cancers. The platforms are equally diverse, representing traditional biologics, cell therapies and vaccines. The panelists who selected the 2017 Small-Cap Biotech Watchlist are George Zavoico of JonesTrading Institutional Services, Raghuram (Ram) Selvaraju of Rodman and Renshaw, and Michael King of JMP Securities. The analysts will discuss their choices in depth at the Biotech Showcase 2017, running Jan. 9-11 at the Hilton San Francisco on Union Square downtown. The Watchlist panel discussion will take place at 8 a.m. on Wednesday, Jan. 11. The Approval Process in Action Infographic Michael King of JMP Securities selected these companies: Pieris Pharmaceuticals Inc. (PIRS:NASDAQ); ~$65M market cap. Pieris Pharmaceuticals has a proprietary biologics platform in the field of anticalins. Multiple therapeutic target areas for the therapy include anemia, asthma and immuno-oncology. WAVE Life Sciences Ltd. (WVE:NASDAQ); ~$723M market cap. This company … Continue reading